Characterizing dose-response I: Critical assessment of the benchmark dose concept

Risk Analysis

Volumn 18, Issue 1, 1998, Pages 13-26

  Murrell, James A ^a   Portier, Christopher J ^b   Morris, Richard W ^a  

^a Research Triangle Institute   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Benchmark dose; Dose response; NOAEL; Noncancer endpoints; Risk assessment

Indexed keywords

BENCHMARK DOSE (BMD); NO OBSERVED ADVERSE EFFECT LEVEL (NOAEL) METHOD;

RISK ASSESSMENT; TOXICITY;

HEALTH RISKS;

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; RETINOL; RETINOL PALMITATE; TRIACYLGLYCEROL; UNSPECIFIC MONOOXYGENASE;

BIOASSAY; CALCULATION; CANCER RISK; DOSE RESPONSE; EXPOSURE; HUMAN; MAXIMUM LIKELIHOOD METHOD; MODEL; NONHUMAN; REGRESSION ANALYSIS; REVIEW; RISK ASSESSMENT; STATISTICS;

ANIMALS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; MALE; MICE; MODELS, STATISTICAL; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PREGNANCY; RATS; RISK ASSESSMENT;

EID: 0032006203     PISSN: 02724332     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1539-6924.1998.tb00911.x     Document Type: Review

References (42)

1. K. S. Crump, "A Method For Determining Allowable Daily Intakes," Fundament Appl. Toxicol. 4, 854-871 (1984).
2. E. A. Weller, P J. Catalono, and P. L. Williams, "Implications of Developmental Toxicity Study Design for Quantitative Risk Assessment," Risk Anal. 15(5) (1995).
3. International Regulatory Liason Group (IRLG), Scientific Bases for Identification of Potential Carcinogens and Estimation of Risks, Federal Register (July 6, 1979).
4. D. Hoel, "Mathematical Dose Response Models and Their Application to Risk Estimation," Proceedings of the Workshop in Quantitative Estimation of Risk to Human Health from Chemicals, Rome, Italy (July 12-16, 1982).
5. D. Krewski, D. Gaylor, and M. Szyskowicz, "A Model-Free Approach to Low-Dose Extrapolation," Environ. Health Perspect. 90, 279-285 (1991).
6. D. W. Gaylor and R. L. Kodell, "Linear Interpolation Algorithm for Low Dose Risk Assessment of Toxic Substances," J. Environ. Pathol. Toxicol. 4, 305-312 (1983).
7. U.S. Environmental Protection Agency (EPA), Guidelines for Carcinogenic Risk, Federal Register 5 (185), 33992-34003 (1996).
8. J. A. Gastel and T. R. Sutter, "Biologically Bounded Risk Assessment for Receptor-Mediated Nongenotxic Carcinogens," Regul. Toxicol. Pharmacol. 22, 273-292 (1995).
9. K. S. Crump, "Calculation of Benchmark Doses from Continuous Data," Risk Anal. 15(1), 79-89 (1995).
10. U.S. Environmental Protection Agency (EPA), Benchmark Dose Technical Guidance Document, EPA/600/P-96/002 (1995).
11. International Program on Chemical Safety (IPCS), IPCS Workshop on the Harmonization of Risk Assessment for Carcinogenicity and Mutagenicity (Germ Cells), International Program on Chemical Safety, Report PCS-C18/445/22, World Health Organization, Geneva, Switzerland (1995).
12. U.S. Environmental Protection Agency (EPA), Health Reassessment Document for 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds (in press).
13. C. A. Kimmel, "Approaches to Evaluating Reproductive Hazards and Risks," Environ. Health Perspect. 101(2), 137-143 (1993).
14. P. M. D. Foster and T. R. Auton, "Application of Benchmark Dose Risk Assessment Methodology to Developmental Toxicity - An Industrial View," Toxicol. Lett. 82-3, 555-559 (1995).
15. J. L. Larson, M. V. Templin, D. C. Wolf, K. C. Jamison, J. R. Leininger, S. A. Mery, K. T. Morgan, B. A. Wong, R. B. Conolly, and B. E. Butterworth, "90-Day Chloroform Inhalation Study in Female and Male B6C3F(1) Mice-Implications for Cancer Risk Assessment," Fundament. Appl. Toxicol. 30(1), 118-137 (1996).
16. F. J. Murray, "A Human Health Risk Assessment of Boron (Boric-Acid and Borax) in Drinking-Water," Regul. Toxicol. Pharmacol. 22(3), 221-230 (1995).
17. C. A. Kimmel, R. J. Kavlock, B. C. Allen, and E. M. Faustman, "The Application of Benchmark Dose Methodology to Data from Prenatal Development Toxicity Studies," Toxicol. Lett. 82-3, 549-554 (1995).
18. P. A. Malsch, D. M. Proctor, and B. L. Finley, "Estimation of a Chromium Inhalation Reference Concentration Using the Benchmark Dose Method - A Case-Study," Regul Toxicol. Pharmacol. 20(1), 58-82 (1994).
19. W. Pease, J. Vandenberg, and K. Hooper, "Comparing Alternative Approaches to Establishing Regulatory Levels for Reproductive Toxicants - DBCP as a Case-Study," Environ. Health Perspect 91, 141-155 (1991).
20. M. Haag-Gronlund, R. Franssonsteen, and K. Victorin, "Application of the Benchmark Method to Risk Assessment of Trichloroethene," Regul. Toxicol. Pharmacol. 21(2), 261-269 (1995).
21. W. Slikker, K. S. Crump, M. E. Andersen, and D. Bellinger, "Biologically-Based, Quantitative Risk Assessment of Neurotoxicants," Fundament. Appl. Toxicol. 29(1), 18-30 (1996).
22. R. J. Kavlock. B. C. Allen, E. M Faustman, and C. A Kimmel, "Dose-Response Assessments for Developmental Toxicity 4. Benchmark Doses for Fetal Weight Changes," Fundament. Appl. Toxicol. 26(2), 211-222 (1995).
23. B. C. Allen, R. J. Kavlock, C. A. Kimmel, and E. M. Faustman, "Dose-Response Assessment for Developmental Toxicity 2: Comparison of Generic Benchmark Dose Estimates with No Observed Adverse Effect Levels," Fundament. Appl Toxicol. 23(4), 487-495 (1994).
24. B. C. Allen, R. J. Kavlock, C. A. Kimmel, and E. M. Faustman, "Dose-Response Assessment for Developmental Toxicity 3: Statistical-Models," Fundament Appl. Toxicol. 23(4), 496-509 (1994).
25. E. M. Faustman, B. C. Allen, R. J. Kavlock, and C A. Kimmel, "Dose-Response Assessment for Developmental Toxicity. 1. Characterization of Database and Determination of No Observed Adverse Effect Levels," Fundament Appl. Toxicol. 23(4), 478-486 (1994).
26. D. G. Barnes, G. P. Daston, J. S. Evans, A. M. Jarabek, R. J. Kavlock, C. A. Kimmel, C. Park, and H. L. Spitzer, "Benchmark Dose Workshop - Criteria for Use of a Benchmark Dose to Estimate a Reference Dose," Regul Toxicol. Pharmacol. 21(2), 296-306 (1995).
27. T. R. Auton, "Calculation of Benchmark Doses from Teratology Data," Regul Toxicol. Pharmacol. 19(2), 152-167 (1994).
28. R. L. Kodell, J. J. Chen, and D. W. Gaylor, "Neurotoxicity Modeling for Risk Assessment," Regul. Toxicol. Pharmacol. 22(1), 24-29 (1995).
29. D. W. Gaylor and W. Slikker, Jr., "Risk Assessment for Neurotoxic Effects," NeuroToxicology 11, 211-218 (1990).
30. K. L. Meier, A. J. Bailer, and C. J. Portier, "A Measure of Tumorigenic Potency Incorporating Dose-Response Shape," Biometrics 49, 917-926 (1993).
31. K. T. Kitchin and J. S. Woods, "2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) Effects on Hepatic Microsomal Cytochrome P-448-Mediated Enzyme Activities," Toxicol. Appl. Pharmacol. 47, 537-546 (1979).
32. K. Abraham, R. Krowke, and D. Neubert, "Pharmacokinetics and Biological Activity of 2,3,7,8-tetrachlordibenzo-p-dioxin: 1. Dose-Dependent Tissue Distribution and Induction of Hepatic Ethoxyresorufin O-Deethylase in Rats Following a Single Injection," Arch. Toxicol. 62, 359-368 (1988).
33. T. R. Narasimhan, A. Craig, L. Arellano, N. Harper, L. Howie, M. Menache, L. Birnbaum, and S. Safe, "Relative Sensitivities of 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Induced Cyp1a-1 and Cyp1a-2 Gene Expression and Immunotoxicity in Female B6C3F1 Mice," Fundament. Appl. Toxicol. 23, 598-607 (1994).
34. D. Davis and S. Safe, "Immunosuppressive Activities of Polychlorinated Dibenzofuran Congeners: Quantitative Structure-Activity Relationships and Interactive Effects," Toxicol Appl Pharmacol. 94, 141-149 (1988).
35. T. A. Mably, D. L. Bjerke, R. W. Moore, A. Gendron-Fitxpatrick, and R. E. Peterson, "In Utero and Lactational Exposure of Male Rats to 2,3,7,8-Tetrachloiodibenzo-p-dioxin: 3. Effects on Spermatogenesis and Reproductive Capability," Toxicol. Appl. Pharmacol. 114, 118-126 (1992).
36. M. J. DeVito, T. Thomas, E. Martin, T. Umbreit, and M. A. Gallo, "Antiestrogenic Action of 2,3,7,8-Tetrachlorodibenzo-p-dioxin: Tissue Specific Regulation of Estrogen Receptor in CD1 Mice," Toxicol. Appl. Pharmacol. 113, 284-292 (1992).
37. A. P. J. M. Van Birgelen, J. Van Der Kolk, K. M. Fase, I. Bol, H. Poiger, A. Brouwer, and M. Van Den Berg, "Subchronic Dose-Response Study of 2,3,7,8-Tetrachlorodibenzo-p-dioxin in Female Sprague-Dawley Rats," Toxicol. Appl. Pharmacol. 132, 1-13 (1995).
38. A. P. J. M. Van Birgelen, E. A. Smit, I. M. Kampen, C. N. Goeneveld, K. M. Fase, J. Van Der Kolk, H. Poiger, M. Van Den Berg, J. H. Koeman, and A. Brouwer, "Subchronic Effects of 2,3,7,8-Tetrachlorodibenzo-p-dioxin or PCBs on Thyroid Hormone Metabolism: Use in Risk Assessment," Eur. J. Pharmacol.; Environ Toxicol. Pharmacol. Sect. 293, 77-85 (1995).
39. R. R. Maronpot, J. F. Foley, K. Takahashi, T. Goldsworthy, G. Clark, A. Tntscher, C. Portier, and G. Lucier, "Dose Response for TCDD Promotion of Hepatocarcinogenesis in Rats Initiated with DEN: Histologic, Biochemical, and Cell Proliferation End Points," Environ. Health Perspect. 101(7), 634-643 (1993).
40. A. M Tritscher, J. A. Goldstein, C. J. Portier, Z. McCoy, G. Clark, and G. Lucier, "Dose-Response Relationships for Chronic Exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin in a Rat Tumor Promotion Model: Quantification and Immunolocalization of CYPIA1 and CYPIA2 in the Liver," Cancer Res. 52, 3426-3442 (1993).
41. D. W. Marquardt, "An Algorithm for Least Squares Estimation of Nonlinear Parameters," J. Soc. Indust. Appl. Math 11, 431-441 (1963).
42. K. Schittkowski, "NLPQL: A FORTRAN Subroutine Solving Constrained Nonlinear Programming Problems," Ann. Operat. Res. 5, 485-500 (1986).